| Property | Value |
|---|---|
| Gene Symbol | PRDM4 |
| Full Name | PR/SET Domain 4 |
| Chromosomal Location | 12q23.3 |
| NCBI Gene ID | 9368 |
| OMIM ID | 605346 |
| Ensembl ID | ENSG00000110635 |
| UniProt ID | Q9Y5A9 |
| Encoded Protein | PR/SET Domain-containing protein 4 |
| Protein Family | PRDM (PRDI-BF1 and RIZ homology domain containing) |
| Molecular Weight | ~68 kDa |
| Tissue Expression | Brain (hippocampus, cortex), neural stem cells, testis, adrenal |
PRDM4 (PR/SET Domain 4) is a member of the PRDM family of transcriptional regulators that encode proteins with SET domain histone methyltransferase activity. The PRDM family comprises at least 16 members (PRDM1-16) characterized by a conserved PR (PRDI-BF1 and RIZ) domain at the N-terminus followed by a SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain at the C-terminus, which confers histone methyltransferase activity [1]. PRDM4 is unique among PRDM proteins in its high expression in neural tissues and its specific role in cognitive function.
The SET domain of PRDM4 primarily catalyzes histone H3K9 trimethylation (H3K9me3), a repressive histone modification associated with gene silencing and heterochromatin formation [2]. However, PRDM4 can also function in a SET-independent manner through protein-protein interactions with transcription factors and co-regulators [3]. This dual functionality allows PRDM4 to both directly silence genes through histone modification and regulate transcription through recruitment of other chromatin-modifying complexes.
PRDM4 encodes a histone H3K9 methyltransferase that preferentially catalyzes H3K9me3 deposition at target gene promoters [2:1]. This activity is central to PRDM4's function as a transcriptional repressor. The enzymatic activity is dependent on the intact SET domain, which contains the catalytic S-adenosyl-L-methionine (SAM)-binding pocket required for methyltransferase function. Mutations in the SET domain can abolish enzymatic activity while retaining some protein-protein interaction functions, suggesting distinct domains for catalytic versus scaffolding roles.
The H3K9me3 mark deposited by PRDM4 recruits heterochromatin protein 1 (HP1) family members, which further stabilize the repressed chromatin state. This mechanism is particularly important in neural stem cells where PRDM4-mediated silencing maintains the balance between proliferation and differentiation by repressing genes that promote premature neuronal differentiation [4].
PRDM4 plays a critical role in maintaining neural stem cell (NSC) identity and regulating the balance between NSC proliferation and differentiation. In embryonic and adult neural stem cells, PRDM4 expression is high and decreases upon differentiation [5]. Knockdown of PRDM4 in NSCs leads to premature neuronal differentiation and reduced proliferation, while overexpression maintains NSCs in a proliferative state [4:1].
The mechanism involves PRDM4-mediated repression of differentiation-promoting genes, including those involved in neurogenic transcription factor networks. PRDM4 interacts with key NSC regulators including REST (RE1-silencing transcription factor) and CoREST complex components to maintain the NSC transcriptome [6]. Additionally, PRDM4 regulates cell cycle progression through direct transcriptional repression of cell cycle inhibitors such as p21 (CDKN1A) and p15 (CDKN2B) [7].
In the adult brain, PRDM4 continues to play important roles in the hippocampus, where adult neurogenesis occurs in the subgranular zone of the dentate gyrus. PRDM4 is expressed in neural progenitor cells (NPCs) in the subgranular zone and promotes NPC proliferation while inhibiting premature differentiation [8]. This function is essential for maintaining the pool of NPCs that give rise to new neurons integrated into hippocampal circuits.
The role of PRDM4 in adult neurogenesis has significant implications for hippocampal-dependent learning and memory. New neurons in the dentate gyrus contribute to pattern separation and cognitive flexibility, processes that are impaired in Alzheimer's disease [9]. Thus, PRDM4 dysfunction may contribute to cognitive decline through impaired neurogenesis.
PRDM4 is expressed in post-mitotic neurons in the hippocampus and cortex, where it regulates genes involved in synaptic plasticity and memory formation [10]. Studies in mouse models have shown that PRDM4 knockdown in the hippocampus impairs long-term memory formation while overexpression enhances memory consolidation [9:1].
The mechanism involves PRDM4-mediated regulation of synaptic protein expression, including AMPA and NMDA receptor subunits, and proteins involved in synaptic vesicle dynamics. PRDM4 also regulates immediate-early genes (IEGs) such as c-Fos and Arc that are critical for activity-dependent synaptic changes. This suggests that PRDM4 participates in the transcriptional program that underlies long-term potentiation (LTP) and long-term depression (LTD), the cellular correlates of learning and memory.
PRDM4 functions as part of multi-protein transcriptional repression complexes. It interacts with histone deacetylases (HDACs), including HDAC1 and HDAC2, which work synergistically with H3K9me3 to generate transcriptionally silent chromatin [11]. PRDM4 also associates with the G9a/GLP complex (EHMT2/EHMT1), another H3K9 methyltransferase, suggesting functional redundancy and cross-talk in heterochromatin formation.
In neurons, PRDM4 interacts with the REST/CoREST complex to repress neuronal gene expression in non-neuronal cells and to fine-tune neuronal gene expression during development and plasticity [6:1]. The REST/CoREST complex is a master regulator of neuronal gene expression, and PRDM4's participation adds another layer of transcriptional control.
PRDM4 has emerging links to Alzheimer's disease (AD) through multiple lines of evidence. Genome-wide association studies (GWAS) have identified PRDM4 polymorphisms as associated with increased AD risk, particularly in European populations [12]. While the effect size is modest, these genetic findings suggest PRDM4 may contribute to AD susceptibility.
At the molecular level, PRDM4 expression is altered in AD brain. Post-mortem studies have shown decreased PRDM4 mRNA and protein in the hippocampus and cortex of AD patients compared to age-matched controls [13]. This decrease correlates with cognitive impairment severity. The mechanisms underlying PRDM4 downregulation in AD may involve:
The functional consequences of PRDM4 loss in AD include:
While less well-studied than AD, PRDM4 may also have relevance to Parkinson's disease (PD). The protein is expressed in dopaminergic neurons, where it may regulate survival pathways. PRDM4 expression is altered in PD brain regions, particularly the substantia nigra. Given PRDM4's role in mitochondrial function and oxidative stress responses—two processes central to PD pathogenesis—further investigation of PRDM4 in PD is warranted.
PRDM4 has been studied in cancer contexts where its expression is often dysregulated. In various cancers, PRDM4 can function as either an oncogene or tumor suppressor depending on context [7:1]. In neural cancers, PRDM4 expression correlates with proliferation and dedifferentiation. The cell cycle regulatory functions of PRDM4 are relevant to both cancer and neurodegeneration, where cell cycle re-entry is a pathological feature.
PRDM4 expression decreases with age in the brain, and this decline is accelerated in age-related cognitive disorders [13:1]. The age-related decrease in PRDM4 may contribute to:
This makes PRDM4 an interesting target for interventions aimed at healthy brain aging.
PRDM4 is expressed throughout the brain with highest expression in the hippocampus and cerebral cortex [15]. Within the hippocampus, PRDM4 is expressed in:
In the cortex, PRDM4 is expressed in both excitatory neurons (pyramidal cells) and inhibitory interneurons. The expression pattern suggests roles in both developmental and adult brain functions.
PRDM4 is a nuclear protein that localizes to the nucleus in both neural stem cells and post-mitotic neurons. The protein contains a nuclear localization signal (NLS) in the PR domain that mediates importin-mediated nuclear import. Within the nucleus, PRDM4 shows both diffuse distribution and focal concentration at heterochromatin regions, consistent with its role in gene silencing.
PRDM4 expression begins during embryonic development and is essential for proper neural development [16]. During embryogenesis, PRDM4 is expressed in the ventricular zone of the developing brain where neural stem cells are located. Expression decreases as neurons differentiate and migrate to their final positions. This developmental expression pattern parallels the adult NSC expression in the subventricular zone and subgranular zone.
PRDM4 intersects with Wnt/β-catenin signaling, a pathway critical for neural development and adult neurogenesis. PRDM4 can be regulated by Wnt signals, and conversely, PRDM4 can modulate Wnt target gene expression. This interaction is particularly relevant to AD, where Wnt signaling is dysregulated.
As a member of the larger TGF-β superfamily of signaling pathways, PRDM4 may interact with SMAD proteins to regulate transcription. The TGF-β pathway is involved in neuroinflammation and neuroprotection, both relevant to neurodegenerative diseases.
PRDM4 interacts with Notch signaling, another critical pathway for neural stem cell maintenance. Cross-talk between PRDM4 and Notch ensures proper timing of neural differentiation.
In AD and other neurodegenerative diseases, global epigenetic changes occur including altered histone modification patterns [14:1]. PRDM4, as a histone methyltransferase, may contribute to or be affected by these changes. The loss of PRDM4 expression in AD may be part of a broader epigenetic dysregulation that affects multiple transcriptional regulators.
Neuroinflammation is a hallmark of AD and PD. In microglial cells, PRDM4 expression is induced by inflammatory stimuli, suggesting a role in the inflammatory response. Chronic neuroinflammation may lead to PRDM4 dysregulation, contributing to neuronal dysfunction.
PRDM4 expression is sensitive to cellular metabolic state. Energy depletion, oxidative stress, and mitochondrial dysfunction—common features of neurodegeneration—affect PRDM4 expression and function. This may create a vicious cycle where metabolic dysfunction reduces PRDM4, leading to further transcriptional dysregulation and impaired cellular homeostasis.
Given PRDM4's roles in neurogenesis, synaptic plasticity, and cognitive function, strategies to enhance PRDM4 activity may have therapeutic potential in AD and other neurodegenerative diseases. Potential approaches include:
However, caution is warranted given PRDM4's complex functions and its links to cancer. Any therapeutic approach would need careful validation in appropriate model systems.
The PRDM family of transcriptional regulators in neural development. ↩︎
Histone H3K9 methylation by PRDM4 in transcriptional regulation. ↩︎ ↩︎
PRDM4 regulates neural stem cell proliferation and differentiation. ↩︎
PRDM4 interacts with key signaling pathways in neurons. ↩︎ ↩︎
Role of PRDM4 in memory formation and synaptic plasticity. ↩︎ ↩︎
Genome-wide association studies identify PRDM4 in Alzheimer's disease risk. ↩︎